



# Rabbit anti-Factor XIIIa

Cat. No.: RBK044 (1 ml Concentrate); RBK044-05 (0.5 ml Concentrate); RBG044 (6 ml Ready-to-use)

## Instructions for use

#### Intended use

This antibody is designed for the specific localisation of Factor XIIIa protein in formalin-fixed, paraffin-embedded tissue sections.

Anti-Factor XIIIa antibody is intended for in vitro diagnostic use.

**Specifications** 

Specificity: Human Factor XIIIa

Clone: EP3372 Isotype: Rabbit IgG

**Species reactivity:** Human +, others not tested

#### **Summary and Description**

The pro-enzyme Factor XIIIa is a blood coagulation factor. It is found in thrombocytes, megakaryocytes and fibroblast-like mesenchymal and histiocytic cells of placenta, uterus, and prostate. Additionally, it is expressed in monocytes and macrophages as well as in dendritic cells of the skin.

The use of antibodies against Factor XIIIa has been found to be helpful for discrimination of dermatofibroma (appr. 90% positive) from dermatofibrosarcoma protuberans (25% positive) and desmoplastic malignant melanoma (negative).

In addition there are some more tumours positive for Factor XIIIa: capillary heamangioblastoma (100% +), heamangioendothelioma (100% +), heamangiopericytoma (100% +), xanthogranuloma (100% +), xanthoma (100% +), hepatocellular carcinoma (93% +), glomus tumour (80% +), and meningioma (80% +).

### Reagent provided

Rabbit monoclonal antibody from tissue culture supernatant in phosphate buffer pH 7.4 including carrier protein and preservative for stabilisation in the following formats:

Concentrate: 1 ml (Cat. No. RBK044)
Concentrate: 0.5 ml (Cat. No. RBK044-05)
Ready-to-use: 6 ml (Cat. No. RBG044)

#### Dilution of primary antibody

Dilution of Zytomed Systems' concentrated antibody depends on the detection system used. The final working dilution must always be determined by the user. The elaboration of staining protocol should be done by an experienced specialist. For Zytomed Systems' recommendations see chapter 'Staining procedure'.

#### Storage and handling

The antibody should be stored at 2-8°C without further dilution.

Dilutions of the concentrated antibody should be done in a suitable antibody dilution buffer (e.g. ZUC025 from Zytomed Systems). The diluted antibody should be stored at 2-8°C after use. The stability of this working solution depends on various parameters and has to be confirmed by appropriate controls.

The antibody provided is suitable for use until the expiry date indicated on the label, if stored at 2-8°C. Do not use product after the expiry date. Positive and negative controls should be run simultaneously with all specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the antibody is suspected, contact Zytomed Systems' technical support or your local distributor.

#### **Precautions**

Use through qualified personnel only.

Wear protective clothing to avoid contact of reagents and specimens with eye, skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with large amounts of water.

Microbial contamination of the reagent must be avoided, since otherwise non-specific staining may occur. Sodium azide (NaN<sub>3</sub>), used for stabilisation, is not considered hazardous material in the concentration used. Reaction of sodium azide with lead or copper in drainage pipes can result in the formation of highly explosive metallic azides. Sodium azide should be discarded in a large volume of running water to avoid formation of deposits. A material safety data sheet (MSDS) for the pure substance is available upon request.

Date of approval: 2023-05-15 Revision: V01 Page 1 of 2

#### Staining procedure for formalin-fixed paraffin sections

Refer to the following table for conditions specifically recommended for this antibody. Also refer to detection system data sheets for guidance on specific staining protocols or other requirements.

<u>Parameters</u> <u>Zytomed Systems recommendations</u>

\*Pre-treatment Heat Induced Epitope Retrieval (for example in Citrate Buffer pH 6.0)

\*Control tissue Dermatofibroma

\*Working dilution 1:100-1:500 (for concentrates)

\*Incubation time 60 minutes

#### **Quality control**

The recommended positive control tissue for this antibody is dermatofibroma. We recommend carrying out a positive and a negative control with every staining run. Please refer to the instructions of the detection system for guidance on general quality control procedures.

#### **Troubleshooting**

If you observe unusual staining or other deviations from the expected results please read these instructions carefully, refer to the instructions of the detection system for relevant information or contact your local distributor.

#### **Expected results**

This antibody stains positive in the cytoplasm in formalin-fixed, paraffin-embedded tissue sections. Further details about the expression pattern of Factor XIIIa can be found in the chapter 'Summary and Description'. Interpretation of the staining results is solely the responsibility of the user. Any experimental result should be confirmed by a medically established diagnostic procedure.

#### **Limitations of the Procedure**

Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining, for example variations in fixation and embedding or the inherent nature of the tissue can cause inconsistent results (Nadji and Morales, 1983). Endogenous peroxidase, peroxidase, pseudoperoxidase activity in erythrocytes or biotin may cause non-specific staining depending on the detection system used. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive results with HRP (horse radish peroxidase) detection systems (Omata *et al*, 1980). Inadequate counterstaining and mounting can influence the interpretation of the results.

Zytomed Systems warrants that the product will meet all requirements described from its shipping date until the expiry date is reached, if the product is stored and utilised as recommended. No additional guarantees can be given. Under no circumstances shall Zytomed System be liable for any damages arising out of the use of the reagent provided.

#### **Performance characteristics**

Zytomed Systems has conducted studies to evaluate the performance of the antibody for use with a standard detection system. The product has been found to be sensitive and specific to the antigen of interest with minimal or no cross-reactivity.

#### **Bibliography**

Dehner LP. Am J Surg Pathol 27:579-593, 2003 Deguchi M et al. Arch Dermatol Res 294:297-302, 2002 Kraus MD et al. Am J Dermatopathol 23:104-111, 2001 Horenstein MG et al. Am J Surg Pathol 24:996-1003, 2000 Demetris AJ et al. Am J Surg Pathol 21:263-270, 1997 Nemes Z, Hum Pathol 23:805-810, 1992 Anstey A et al. Am J Dermatopathol 16:14-22, 1994 Glusac EJ et al. Am J. Surg Pathol 18:583-590, 1994 Abenoza P, Lillemoe T. Am J Dermatopathol 15:429-434, 1993 Nadji M and Morales AR Ann N.Y. Acad Sci 420:134-9, 1983 Omata M et al. Am J Clin Pathol 73(5): 626-32, 1980



www.zytomed-systems.de
Zytomed Systems GmbH • Anhaltinerstraße 16 • 14163 Berlin, Germany • Tel: (+49) 30-804 984 990

## Explanations of the symbols on the product label

Symbols are used in accordance with ISO 15223-1. Further symbols on the product label might be:



GSH07: Warning / Attention

For Research Use Only

Date of approval: 2023-05-15 Revision: V01 Page 2 of 2